Dr Reddys rolls out new generic Ozempic brands
Dr Reddys Laboratories has expanded its generic semaglutide portfolio with two new brands after supply issues halted sales of its original Obeda injection in India. The company introduced Obeda Pro and Obeda Plus manufactured by Hetero Labs following an earlier product recall.
Xurve View
Insights:
Xurve View
Dr. Reddy's Laboratories rolled out two new generic semaglutide brands, Obeda Pro and Obeda Plus, in India following supply disruptions that halted sales of its original Obeda injection. The launch expands the drugmaker's portfolio in the country's fast-growing semaglutide market. The expansion comes as domestic competition intensifies following the patent expiration of NOVO NORDISK A/S-B's blockbuster diabetes and weight-loss drugs.
